|Specificity:||The antibody MEM-48 recognizes an epitope involving residues 534-546 in cysteine-rich repeat 3 of the CD18 antigen (integrin beta2 subunit; beta2 integrin). CD18 is a 90-95 kDa type I transmembrane protein expressed on all leukocytes.|
|Immunogen:||Leukocytes of a patient suffering from a LGL-type leukemia.|
|Negative Species:||Canine (Dog)|
|Preparation:||The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC and adjusted for direct use. No reconstitution is necessary.|
|Storage Buffer:||The reagent is provided in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide.|
|Storage / Stability:||Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.|
|Usage:||The reagent is designed for Flow Cytometry analysis of human blood cells using 20 μl reagent / 100 μl of whole blood or 106 cells in a suspension.
The content of a vial (0.5 ml) is sufficient for 25 tests.
|Expiration:||See vial label|
|Lot Number:||See vial label|
|Background:||CD18, integrin beta2 subunit, forms heterodimers with four types of CD11 molecule to constitute leukocyte (beta2) integrins: alphaLbeta2 (CD11a/CD18, LFA-1), alphaMbeta2 (CD11b/CD18, Mac-1, CR3), alphaXbeta2 (CD11c/CD18) and alphaDbeta2 (CD11d/CD18). In most cases, the response mediated by the integrin is a composite of the functions of its individual subunits. These integrins are essential for proper leukocyte migration, mediating intercellular contacts. Absence of CD18 leads to leukocyte adhesion deficiency-1; severe reduction of CD18 expression leads to the development of a psoriasiform skin disease. CD18 is also a target of Mannheimia (Pasteurella) haemolytica leukotoxin and is sufficient to mediate leukotoxin-mediated cytolysis.|
*Gao JX, Issekutz AC: Mac-1 (CD11b/CD18) is the predominant beta 2 (CD18) integrin mediating human neutrophil migration through synovial and dermal fibroblast barriers. Immunology. 1996 Jul;88(3):463-70.
*Drbal K, Angelisova P, Cerny J, Pavlistova D, Cebecauer M, Novak P, Horejsi V: Human leukocytes contain a large pool of free forms of CD18. Biochem Biophys Res Commun. 2000 Aug 28;275(2):295-9.
*Shang XZ, Issekutz AC: Contribution of CD11a/CD18, CD11b/CD18, ICAM-1 (CD54) and -2 (CD102) to human monocyte migration through endothelium and connective tissue fibroblast barriers. Eur J Immunol. 1998 Jun;28(6):1970-9.
*Kess D, Peters T, Zamek J, Wickenhauser C, Tawadros S, Loser K, Varga G, Grabbe S, Nischt R, Sunderkötter C, Müller W, Krieg T, Scharffetter-Kochanek K: CD4+ T cell-associated pathophysiology critically depends on CD18 gene dose effects in a murine model of psoriasis. J Immunol. 2003 Dec 1;171(11):5697-706.
*Solovjov DA, Pluskota E, Plow EF: Distinct roles for the alpha and beta subunits in the functions of integrin alphaMbeta2. J Biol Chem. 2005 Jan 14;280(2):1336-45.
*Peters T, Sindrilaru A, Wang H, Oreshkova T, Renkl AC, Kess D, Scharffetter-Kochanek K: CD18 in monogenic and polygenic inflammatory processes of the skin. J Investig Dermatol Symp Proc. 2006 Sep;11(1):7-15.
*Dassanayake RP, Maheswaran SK, Srikumaran S: Monomeric expression of bovine beta2-integrin subunits reveals their role in Mannheimia haemolytica leukotoxin-induced biological effects. Infect Immun. 2007 Oct;75(10):5004-10.
*Bazil V, Stefanova I, Hilgert I, Kristofova H, Vanek S, Horejsi V.: Monoclonal antibodies against human leucocyte antigens. IV. Antibodies against subunits of the LFA-1 (CD11a/CD18) leucocyte-adhesion glycoprotein. Folia Biol (Praha). 1990;36(1):41-50.
*Larson RS, Springer TA: Structure and function of leukocyte integrins. Immunol Rev. 1990 Apr;114:181-217.
*Stefanova I, Horejsi V: Association of the CD59 and CD55 cell surface glycoproteins with other membrane molecules. J Immunol. 1991 Sep 1;147(5):1587-92.
*Garnotel R, Rittié L, Poitevin S, Monboisse JC, Nguyen P, Potron G, Maquart FX, Randoux A, Gillery P: Human blood monocytes interact with type I collagen through alpha x beta 2 integrin (CD11c-CD18, gp150-95). J Immunol. 2000 Jun 1;164(11):5928-34.
*Ottonello L, Epstein AL, Dapino P, Barbera P, Morone P, Dallegri F: Monoclonal Lym-1 antibody-dependent cytolysis by neutrophils exposed to granulocyte-macrophage colony-stimulating factor: intervention of FcgammaRII (CD32), CD11b-CD18 integrins, and CD66b glycoproteins. Blood. 1999 May 15;93(10):3505-11.
*Schiff DE, Rae J, Martin TR, Davis BH, Curnutte JT: Increased phagocyte Fc gammaRI expression and improved Fc gamma-receptor-mediated phagocytosis after in vivo recombinant human interferon-gamma treatment of normal human subjects. Blood. 1997 Oct 15;90(8):3187-94.
*Kuttruff S, Koch S, Kelp A, Pawelec G, Rammensee HG, Steinle A: NKp80 defines and stimulates a reactive subset of CD8 T cells. Blood. 2009 Jan 8;113(2):358-69.
For laboratory research only, not for drug, diagnostic or other use.
EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic